The HSP90 Inhibitor Ganetespib Synergizes With the MET Kinase Inhibitor Crizotinib in Both Crizotinib-Sensitive and -Resistant MET-Driven Tumor Models

Cancer Research - United States
doi 10.1158/0008-5472.can-13-1156
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non–small Cell Lung Cancer

American Journal of Clinical Oncology: Cancer Clinical Trials
Cancer ResearchOncology
2015English

Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

The New-Generation Selective ROS1/NTRK Inhibitor DS-6051b Overcomes Crizotinib Resistant ROS1-G2032R Mutation in Preclinical Models

Nature Communications
AstronomyGeneticsMolecular BiologyBiochemistryChemistryPhysics
2019English

An Orally Bioavailable C-Met Kinase Inhibitor Potently Inhibits Brain Tumor Malignancy and Growth

Anti-Cancer Agents in Medicinal Chemistry
Cancer ResearchMolecular MedicinePharmacology
2010English

Development of Crizotinib, a Rationally Designed Tyrosine Kinase Inhibitor for Non-Small Cell Lung Cancer

International Journal of Cancer
Cancer ResearchOncology
2017English

Identification of a Novel MET Exon 14 Skipping Variant Coexistent With EGFR Mutation in Lung Adenocarcinoma Sensitive to Combined Treatment With Afatinib and Crizotinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Patients Harboring EGFR Mutation After Primary Resistance to Crizotinib and Response to EGFR-tyrosine Kinase Inhibitor

OncoTargets and Therapy
OncologyPharmacology
2016English

Met Tyrosine Kinase Inhibitor, PF-2341066, Suppresses Growth and Invasion of Nasopharyngeal Carcinoma

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2015English

Response to Crizotinib in a Patient With MET-mutant Papillary Renal Cell Cancer After Progression on Tivantinib

European Urology
Urology
2015English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy